RxDoctor Payments Data

Kelly Link, NP

Family · Salem, VANPI 1942632344

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,672 of the $10,928 with a category attached, or 70.2%. Inspire Medical Systems, Inc. accounts for 82.4% of it on its own, with 18 other manufacturers making up the rest. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,928in general payments, 2019–2025

Across 208 payments — averaging $52.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$9K
  • Harmony Biosciences LLC$332
  • Axsome Therapeutics, Inc.$287
  • Avadel CNS Pharmaceuticals, LLC$186
  • United Therapeutics Corporation$168
  • Lilly USA, LLC$126
  • plus $829 from 13 others

What the payments were for

  • Travel & lodging$3,09328%
  • Food & beverage$7,67270%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,928 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$48,529
Medicare patients
350
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl13$93,518
QuviviqDaridorexant Hcl12$9,690
BelsomraSuvorexant12$7,790
Modafinil29$5,790
Armodafinil12$1,292
Imipramine Hcl12$171
Zolpidem Tartrate17$106
Trazodone Hcl24$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$332$93,51813 claims
Idorsia Pharmaceuticals US IncQuviviq$51$9,69012 claims
MerckBelsomra$21$7,79012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →